Pure Green Pharmaceutical recently released the results from their placebo controlled clinical trial for diabetic patients with moderate to severe neuropathic pain. The confirmatory double blind, placebo-controlled trial showed statistically and clinically significant improvement in average and highest pain scores for those patients who received Pure Green’s water-soluble CBD sublingual tablets. 

The water-soluble CBD sublingual tablets from Pure Green show not only improvement in pain score, but also in sleep quality and anxiety. Through the study, 54 painful diabetic peripheral neuropathy patients were randomized and either received the CBD tablets in 20 mg of water three times daily, or a placebo for 28 days. Reporting no adverse events in the clinical trial, the results show a drop in pain scores by about 50 percent. 

Pure Green CEO, Stephen Goldner said: "A collaborative drug development meeting with FDA set us on this path and we look forward to returning to FDA to share this data. FDA is keen to relieve patient suffering in this very large patient population, especially since COVID-19 appears to have increased the number of diabetic patients."